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1. Introduction 
MicroRNAs (miRNAs) are single-stranded, highly conserved, short non-coding RNAs (~ 22 
nucleotides) regulating target gene expression by base pairing with specific sequences of 
target mRNAs (Ambros, 2004). miRNAs negatively regulate gene expression post-
transcriptionally by suppressing translation and/or inducing mRNA degradation. 
Bioinfomatically, it is estimated that human genome may contain approximately 1000 
miRNAs (Bartel, 2004; Berezikov et al., 2005; Griffiths-Jones et al., 2008) and consistently, 
additional miRNAs are continually being identified (Griffiths-Jones et al., 2006). miRNAs 
modulate the expression of target proteins in a non-canonical manner by binding to specific 
sequences regulating functional networks. Consequentially, a single miRNA might target 
hundreds of distinct genes or alternatively expression of a single coding gene can be 
regulated by many different miRNAs (Lewis et al., 2005; Miranda et al., 2006). Recent 
studies show the important role of miRNAs in the regulation of a variety of physiological 
functions ranging from stem cell differentiation to cardiac muscle development and stress 
(Krichevsky et al. 2006; Chen et al., 2006; Zhao et al., 2005; Pedersen et al., 2007; Kloosterman 
et al., 2007; Felli et al., 2005; Tay et al., 2008). Furthermore, aberrant expression of miRNAs 
has been found in various diseases including cancer, diabetes and cardiac 
hypertrophy/failure.  
The binding specificity of miRNAs depend on complementary base pairing of ~ 7 nucleotide 
seed sequence region at the 5’ end of the miRNA with the corresponding mRNA target. 
Another caveat that needs to be considered in the miRNA regulation is the miRNA 
sequences outside the 7 nucleotide seed region which pairs with the mRNA that may also 
play a role in determining the strength/efficacy of regulating the target mRNA. The binding 
of miRNAs to their cognate target mRNAs commonly results in decreased expression of 
target genes through translational repression or mRNA degradation (Fig. 1). Conversely, 
decreased expression of miRNAs will lead to increased target gene expression (Gregory et 
al., 2008).  
This realm of knowledge has allowed for studies on miRNAs on their tissue specificity and 
disease specificity but critically little information is available with regards to temporal or 
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spatial expression profiles of miRNAs in the heart. By and large studies have used micro-
array analysis to identify altered miRNAs to define signature of altered miRNAs in a 
specific cardiac phenotype. As miRNAs target multiple proteins, these signatures have been 
used to predict the array of molecules altered. Over time sophisticated computational 
approaches have been developed that has lead to identification of previously unrecognized 
targets within disease pathways of interest (Ivanovska and Cleary, 2008; Gusev et al., 2007). 
Among the computational tools the most commonly used target prediction algorithms 
include DIANA-microT (Kiriakidou et al., 2004), miRanda (Griffiths-Jones et al., 2006), 
TargetScan (Lewis et al., 2003), TargetScanS (Lewis et al., 2005), PicTar (Krek et al., 2005) and 
PITA (Kertesz et al., 2007). These algorithms rely on criteria like conservation among 
species, seed complementarity, thermo-stability of miRNA-mRNA hybrids, delta G of target 
mRNA binding site, and multiple miRNA binding sites in the 3’UTR (cooperativity) to 
predict targets (Bartel, 2009; Cacchiarelli et al., 2008; Ivanovska and Cleary, 2008; Gusev et 
al., 2007). Thus, use of these algorithms provide hundreds of targets indicating that miRNA 
alteration in expression could have wide ranging effects on molecules belonging to multiple 
signaling pathways. It is important to note that target prediction with these algorithms 
remains challenging but these are the tools currently available in field to provide a window 
into understanding the role of miRNAs. These predicted targets can then be used as a 
platform for identifying signaling pathways and networks that are altered manifesting in 
the phenotype. Critically these bioinformatic tools are evolving with the field and are 
pivotal to understanding the global role of miRNAs in cardiomyopathy. Although miRNA 
regulation adds another layer of complexity to the already complex etiology, understanding 
the regulation could provide novel therapeutic strategies due to miRNAs ability to target 
multiple molecules. In this regard, the focus of our article is to provide an overview of 
altered miRNAs in cardiac stress and the available tools that could be used to understand 
their global implications.  
2. miRNA generation 
2.1 Genome distribution, miRNA processing and nuclear export 
miRNAs are encoded by their own genes which are an integral part of cell’s genetic make up 
and are evolutionarily conserved (Ambros, 2004; Bartel, 2004). miRNAs can be transcribed as 
polycistronic primary transcripts or as individual transcripts from intergenic regions, exon 
sequences of non-coding strand or intronic sequences (Kim and Nam, 2006; Altuvia, et al., 
2005) (Fig. 1). Intronic miRNAs are generally transcribed coincidentally with the gene and 
excised by the splicing machinery from the larger gene transcript in which they are embedded 
(Rodriguez et al., 2004). Indeed, intronic miRNAs may represent a simple way for a protein-
coding gene to regulate other protein-coding genes in a non-canonical manner. miRNAs are 
transcribed by the RNA polymerase II as a primary transcript several kilobases long 
characterized by stem-loop hairpin structures called pri-miRNAs that are 5’ capped and a poly 
(A) to stabilize these pre-miRNAs similar to that of the traditional mRNAs (Lee et al., 2004). 
The generated pre-miRNA is processed in the nucleus and exported out through a regulated 
process. The stem-loop structures of pre-miRNAs are recognized by Drosha (a double-
stranded specific RNase III) and its partner DGCR8 (a double stranded RNA binding protein) 
that cleave at the hair-pin base to release ~ 70-90 nucleotide stem-loop pri-miRNA precursor 
(Lee et al., 2003, 2004). In addition to this classical pathway, recent studies have identified 
alternate pathway wherein intronic pre-miRNA precursors “mirtrons” uses the cellular 
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splicing machinery to bypass Drosha mediated processing (Ruby et al., 2007; Okamura et al., 
2007) . The cleaved stem-loop pre-miRNA hairpins are exported into the cytoplasm by the 
exportin-5 (a Ran-GTP-dependent nuclear transport receptor) (Yi et al., 2003). The interaction 
of exportin-5 with the pre-miRNA ‘minihelix motif’ (~14 nucleotide stem and a short 30 
nucleotide overhang) is thought to stabilize the pre-miRNAs (Yi et al., 2003; Filipowicz, 2005) 
manifesting in efficient transport. 
 
 
Fig. 1. MicroRNA (miRNA) genomic organization, biogenesis and function 
Genomic distribution of miRNA genes. TF: transcription factor. (A) Clusters throughout the 
genome transcribed as polycistronic primary transcripts and subsequently cleaved into 
multiple miRNAs; (B) intergenic regions transcribed as independent transcriptional units; 
(C) intronic sequences of protein-coding or -non-coding transcription units or exonic 
sequences (black cylinders) of non-coding genes. Primary miRNAs(pri-miRNAs) transiently 
have a 7- methylguanosine (7mGpppG) cap and a poly(A) tail. The pri-miRNA is processed 
into a precursor miRNA (pre-miRNA) stem-loop of 60 nucleotides (nt) in length by the 
nuclear RNase III enzyme Drosha and its partner DiGeorge syndrome critical region gene 8 
(DGCR8). Exportin-5 actively transports pre-miRNA into the cytosol, where it is processed 
by the Dicer RNaseIII enzyme, together with its partner TAR (HIV) RNA binding protein 
(TRBP), into mature, 22 nt-long double strand miRNAs. The RNA strand (in red) is recruited 
as a single-stranded molecule into the RNA-induced silencing (RISC) effector complex and 
assembled through processes that are dependent on Dicer and other double strand RNA 
binding domain proteins, as well as on members of the Argonaute family. Mature miRNAs 
then guide the RISC complex to the 3’ untranslated regions (3’-UTR) of the complementary 
messenger RNA (mRNA) targets and repress their expression by several mechanisms: 
repression of mRNA translation, destabilization of mRNA transcripts through cleavage, de-
adenylation, and localization in the processing body (P-body), where the miRNA-targeted 
mRNA can be sequestered from the translational machinery and degraded or stored for 
subsequent use. Nuclear localization of mature miRNAs has also been described and is a 
novel mechanism of action for miRNAs.  
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2.2 Generation of mature miRNA, activation and target recognition 
The pre-miRNA is processed into a mature miRNA of ~22 nucleotides long by another 
double stranded RNase III called the Dicer (Hutvagner et al., 2001). Single stranded RNA is 
assembled into a RNA-inducing silencing complex (RISC) with the help of Dicer, TAR (HIV) 
RNA binding protein (TRBP), and dsRNA-binding proteins of the argonaute (AGO) family 
(Chapman and Carrington, 2007; Filipowicz, 2005; Schwarz et al., 2003; MacRae et al., 2008; 
Okamura et al., 2004). Additional factors have also been isolated and implicated (Chapman 
and Carrington, 2007; Filipowicz, 2005; Schwarz et al., 2003; MacRae et al., 2008; Okamura et 
al., 2004) to be a part of RISC complex bringing about miRNA-mediated silencing of gene 
expression that could be either a translational repression or degradation of mRNA. miRNAs 
recognize their target mRNAs through specific interaction of the 5’ end ‘seed’ region (2–8 nt 
from the 5’ end) and the complementary sequences of conserved target mRNAs (Bartel, 
2004). Since only a few miRNAs have perfect complementarity to the target mRNAs leading 
to degradation, majority of the miRNAs have imperfect match resulting in translational 
repression (Nilsen, 2007). Another caveat in the miRNA silencing dynamics is the ability of 
multiple miRNAs to bind to the same mRNA initiating translational repression with 
different potencies. Repressed mRNAs are sequestered from translational machinery, 
degraded or stored for subsequent use in large macroscopic cytoplasmic foci, named 
processing bodies (P-bodies) upon silencing by miRNAs. The P-bodies contain a wide range 
of enzymes involved in RNA turnover, including de-capping enzymes, de-adenylases and 
exonucleases (Eulalio et al., 2007).  In addition to their cytoplasmic role, miRNAs with 
nuclear localization sequence have been identified demonstrating their role in 
transcriptional control of gene expression (Chapman and Carrington, 2007; Volpe et al., 
2002; Zilberman, et al., 2003; Aravin et al., 2007; Yu et al., 2008; Hwang et al., 2007; Calin et 
al., 2007). 
3. miRNAs and cardiac development 
3.1 miRNA expression in cardiac development 
Studies have shown that miRNA mediated fine tuning leads to critical cell lineage 
commitment and embryonic tissue development (Latronico, et al., 2007; Farh et al., 2005; 
Ivey et al., 2008). Consistent with the role of miRNA in development, deletion of Dicer leads 
to embryonic lethality resulting from defects in cardiogenesis due to deficiencies in miRNAs 
biogenesis (Giraldez et al., 2006; Ebert et al., 2007). In tune with complex process of 
cardiogenesis many miRNAs are shown to be involved and the selection of miRNAs 
enriched during the differentiation of mouse embryonic stem cells to cardiomyocytes are 
detailed in Table 1 (Lakshmipathy et al., 2007; Thum et al., 2007). Significant increase in 
miRNA expression with development shows that miRNAs play an important role in early 
embryonic patterning and orchestrating organogenesis (Ivey et al., 2008). Expression pattern 
of miRNA-1 and -133 show that these two miRNAs play a key role in skeletal muscle 
proliferation and differentiation (Chen et al., 2006). Specifically, miRNA-1 promotes 
myogenesis by targeting histone deacetylase (HDAC4), a transcriptional repressor while 
miRNA-133 enhances myoblast proliferation by repressing serum response factor (SRF) 
(Zhao et al., 2005, 2007; Kwon et al., 2005; Niu et al., 2007). In this context, loss of function of 
miRNA-1 in Drosophila results in embryonic/larval lethality due to altered sarcomeric gene 
expression and increased number of undifferentiated muscle progenitors (Kwon et al., 2005). 
Where as miRNA-1 gain of function results in embryonic lethality due to insufficient 
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numbers of cardioblasts indicating that cardiogenesis and differentiation is a spatio-
temporal process tightly regulated by miRNA-1 mediated by cardiac transcription factor 
Hand2 (Zhao et al., 2005; Srivastava et al., 1997). Another important component of miRNA 
expression is the Dicer mediated generation of miRNA during development. Dicer 
expression during development determines miRNA expression and its regulation. Indeed, 
Dicer-deficient animals fail to synthesize new miRNAs resulting in embryonic lethality in 
zebrafish (Giraldez et al., 2005) and mice (Bernstein et al., 2003). More importantly cardiac 
specific deletion of Dicer results in aberrant cardiac contractile protein expression and 
severe sarcomere disarray, leading to progressive dilated cardiomyopathy (DCM), failure 
and postnatal lethality (Chen et al., 2008). 
 
 
Table 1. Summary of regulated microRNAs (miRNAs) in cardiac development and disease. 
3.2 Regulation of miRNA transcription 
Understanding transcriptional regulation of miRNAs is critical as expression of miRNAs is a 
major determinant of miRNA dependent regulatory mechanisms. As miRNAs are 
transcribed like other genes, they are regulated by transcription factors and expression of 
transcription factors determines the miRNA expression. SRF is a cardiac enriched 
transcription factor that regulates sarcomere organization in the heart and SRF expression 
follows a restrictive pattern during development (Olson and Schneider, 2003; Niu et al., 
2007; Barron et al., 2005). SRF expression is very important as multiple SRF binding sites 
have been identified in promoters of genes regulating contractility, cell movement, and 
growth signaling (Sun et al., 2006; Zhang et al., 2005). Consistent with the role of SRF in 
cardiac development, several miRNAs have been identified to contain SRF binding sites in 
their promoter including miRNA-1-1, -1-2, -21, -206, -214, -133 and others (Niu et al., 2007). 
In addition, studies have unequivocally have shown that miRNA-1-1, -1-2 and -133 are 
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regulated by SRF transcription factor alone or in conjunction with co-factors like GATA5, 
MyoD, Nkx 2.5 or MEF2 (Fig. 2) (Zhao et al., 2005; Chen et al., 2006; Niu et al., 2007; Rao et 
al., 2006; Xiao et al., 2007). It is important to note that the outlined co-factors of SRF by 
themselves can act as transcriptional regulators in their own right increasing complexity of 
regulation. For example, MEF2 along with MyoD is known to regulate miRNA-1-2/133a-1 
in myotomes during embryogenesis and all skeletal fibers in adulthood (Liu et al., 2007).  
3.3 miRNA expression patterns 
miRNA expression is greatly enriched in a tissue/cell-specific manner indicating unique 
signature patterns for each type. This enrichment and signature pattern suggests that miRNAs 
play a critical role in regulating and maintaining the specific cellular phenotype which is of 
essence in an organ with diverse cell/tissue types contributing to effective functioning. In this 
regard, heart as an organ contains many “non-cardiomyocyte” cell types like endothelial cells, 
smooth muscle cells and fibroblasts and each of which have distinct function in the heart. 
Consistently, differential enrichment of miRNAs are observed in cardiomyocyte versus cardiac 
fibroblasts indicating important role in cellular specificity (Landgraf et al., 2007; Kuehbacher et 
al., 2007; Harris et al., 2008). Although specific miRNA enrichments are being found in 
different cell types (Kuehbacher et al., 2007; Harris et al., 2008), lot more work needs to be done 
to determine contribution of miRNAs towards regulation of global networking pathways that 
defines specific fingerprints for each cell type. The current studies have all been focused on one 
or two miRNAs (Chen et al., 2006; Gregory et al., 2008; Harris et al., 2008) which by themselves 
may not be sufficient to determine a cellular phenotype indicating requirement of more 
comprehensive studies on specific miRNAs signature for cellular phenotype. 
4. miRNAs and cardiac disease 
The heart is responsive to physiological stimuli or pathological stress and accordingly 
undergoes remodeling to meet the demand (Catalucci et al., 2008). Following stress, the 
heart undergoes extensive remodeling in the form of physiological or pathological 
hypertrophy defined as an augmentation of ventricular mass due to increased 
cardiomyocyte size. Cardiac hypertrophy is characterized by initial compensatory 
mechanisms that adapt the heart towards sustaining the cardiac output. However, this 
process is only an initial ‘adaptive’ response and chronic exposure to stress eventually leads 
to impaired function that, in many cases, progresses to failure. This maladaptive change is 
accompanied by alterations in the underlying molecular map including a switch in the gene 
expression program leading to reexpression of fetal genes (Catalucci et al., 2008; Thum et al., 
2007). The involvement of miRNAs in this pathological process has been recognized and is 
thought to be integral ‘switch’ in the gene expression program. Intense efforts have been put 
into identifying miRNAs altered in pathology and evolving signature of deregulated 
miRNAs identified cardiac disease is detailed in Table 2. 
4.1 Myocardial hypertrophy, remodeling, and heart failure 
Cardiac remodeling is characterized by structural alterations of myocardial tissue, 
modification of the extracellular matrix, and reshaping of left ventricle geometry and 
performance (Catalucci et al., 2008; Dash et al., 2001). The presence of chronic stress results 
in deleterious remodeling.  
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Table 2. miRNAs experimentally determined to play a role in cardiac hypertrophy/ 
cardiomyopathy 
Multiple studies have been carried out to reveal important roles of miRNAs in cardiac 
hypertrophy and heart failure. Studies have found that a unique set of miRNAs are 
upregulated, downregulated or unaltered during the adaptive response of the heart to stress 
stimuli (Latronico et al., 2007). Furthermore, unique subset of miRNAs are known to be 
altered within the various etiologies of heart failure indicating significant role of miRNAs in 
these disease states (Sucharo et al., 2008). Consistent with the reexpression of fetal gene 
program, a high degree of similarity has been found between the miRNA expression pattern 
occurring in failing human hearts and those observed in the 12- 14 week-old hearts (Thum et 
al., 2007). Approximately, 80% of the analyzed miRNAs are similarly altered in failing adult 
and fetal human hearts compared to non-failing hearts. Multiple miRNAs have been 
implicated in cardiomyocyte hypertrophy and studies have consistently found upregulation 
of miRNA-21, -23a, -23b, -24, -195, -199a and miR-214 and downregulation of miRNA-1, -7, -
133 and 378 (Naga Prasad and Karnik, 2010). Many of these miRNAs have been tested for 
hypertrophic response in neonatal cardiomyocytes. Concordant data from human and mice 
samples indicate that miRNAs may be involved in common pathway mediating 
hypertrophic response (Thum et al., 2007; van Rooij et al., 2006; Chen et al., 2008;  Ikeda et 
al., 2007; Tatsuguchi et al., 2007; Sayed et al., 2007; Cheng et al., 2007) .  
Among the miRNAs altered in various cardiac etiologies, some of them have been studied 
indepth and these include miRNA-1, -21, -133 and -208. It is well known that miRNA-1 is 
downregulated with a week of transverse aortic banding and its expression is inversely 
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correlated with cardiac hypertrophy (Table 2) (Sayed et al., 2007; Catalucci et al., 2008; Ikeda et 
al., 2009, Naga Prasad et al., 2009 after al., 2009)). Similarly, Care et al., observed impaired 
expression of both miR-1 and miR-133 in patients with hypertrophic cardiomyopathy and atrial 
dilatation as well as in 3 different murine models of cardiac hypertrophy (Catalucci et al., 2008). 
In vitro cellular overexpression of miRNA-133 resulted in suppression of protein synthesis and 
block in hypertrophic response. Contrastingly, utilization of a decoy for miRNA-133 resulted in 
cellular hypertrophy and in vivo administration resulted in significant myocardial hypertrophy 
associated with reexpression of the fetal gene program (Catalucci et al., 2008). Some of targets of 
miRNA-133 have been validated and many are still being validated to provide evidence of 
miRNA-133 targeting multiple molecules to bring about hypertrophic response. miRNA-133 is 
encoded by 133a-1 and –2 and deletion of individual miRNA have no obvious cardiac 
abnormalities but combined deletion results in severe cardiac malformations with embryonic 
and post-natal lethality (Care et al., 2007). In contrast, overexpression of miRNA-133a results in 
embryonic lethality (E 15.5) caused by ventricular septal defected and impaired cardiomyocyte 
proliferation resulting in thinning of ventricular walls unable to meet hemodynamic needs 
(Care et al., 2007). These studies reveal that miRNA-133 plays a key role in myocardial 
development, hypertrophy and function. miRNA-208 is unique as it is a cardiac-specific 
miRNA encoded within the intron of ǂ-myosin heavy chain (ǂ-MHC) gene. miR-208 knockout 
mice are viable and do not show any obvious cardiac phenotype, but they fail to undergo stress-
induced cardiac remodeling, hypertrophic growth, and ǂ-MHC upregulation following 
transverse aortic constriction (Table 2) (van Rooij et al., 2007). It is believed that miRNA-208 
regulation of this process involves ǂ-MHC alterations balancing ǂ-MHC.  
While miRNA-208 mediates cardiac function by cardiomyocyte specific expression, miRNA-21 
regulates cardiac function by its expression in both myocytes as well as cardiac fibroblasts. 
Recent studies (Thum et al., 2008) have shown progressive upregulation of miR-21 during late 
stages of heart failure, with an expression profile restricted exclusively to cardiac fibroblasts 
(Table 2). Upregulation of miR-21 was shown to be responsible for increased extracellular 
signal-regulated kinase (ERK) signaling through inhibition of its target, spry1 (sprouty 1), an 
inhibitor of the ERK/extracellular signal-regulated kinase pathway. These studies suggest that 
miRNA-21 expression results in increased fibroblast survival and reduced interstitial fibrosis 
independent of cardiomyocyte loss that may provide protective effects (Thum et al., 2008). 
Likewise, it has been (van Rooij et al., 2008) recently demonstrated that downregulation of the 
fibroblast-enriched miRNA-29 family in fibrotic areas surrounding a cardiac infarct is 
responsible for the regulation of mRNAs that encode a multitude of proteins involved in 
fibrosis such as collagens, fibrillins, and elastins. In addition to these miRNAs, we have recently 
shown that 8 miRNAs are differentially expressed in human dilated cardiomyopathy (DCM) 
(Naga Prasad et al., 2009). The miRNA-1, -29b, -7, and -378 were significantly down-regulated 
in the DCM samples compared with non-failing controls. In contrast, miRNA-214, -342, -125b 
and -181b were significantly upregulated in DCM compared with non-failing controls. These 
studies identified miRNA-7 and -378 as novel miRNAs which are significantly downregulated 
during end stage cardiac dysfunction whose role in cardiac pathology remains to be 
determined. 
4.2 Arrhythmia 
One of the well known contributing factors for heart failure are the changes in ion channel 
function and expression leading to electrophysiological remodeling in both atria and 
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ventricles. Although the role of miRNAs with regard to arrhythmia is not yet well 
established, recent evidence supports their role in the induction of arrhythmia. Expression 
of miRNA-1 by viral transduction following myocardial infarction in rat resulted in 
significant enlargement of the QRS complex, prolongation of the QT interval, and an 
increased incidence of arrhythmias (Yang et al., 2007). Conversely, a low incidence of fatal 
arrhythmias was obtained when antisense for miRNA-1 was used. These studies further 
identified that miRNA-1 targets GJA1 (connexin 43) and KCNJ2 a critical K+ channel subunit 
both of which are required for maintenance of membrane potential. Consistently, miRNA-1 
and -2 double knockout mice that survived until birth had high incidence of 
electrophysiological abnormalities resulting in sudden death (Zhao et al., 2007). In addition 
to miRNA-1, miRNA-133 has been implicated in contributing towards cardiac disease by 
altering electrophysiological remodeling. In particular, downregulation of miRNA-133 in 
hypertrophic hearts has been associated with an increase in ion channels HCN2/HCN4 
which when upregulated, enhance automaticity and the development of arrhythmia (Luo et 
al., 2008). Moreover, in a model of diabetic cardiomyopathy, overexpression of miR-133 has 
been shown to downregulate the ERG (ether a-go-go-related gene) with consequent QT 
prolongation responsible for arrhythmias (Xiao et al., 2007). Although only two miRNAs 
have been extensively studied with regards to arrhythmia, it is only matter of time that more 
miRNAs will be found to play a critical contributing role in complex electrophysiological 
remodeling that may cause heart failure and sudden death. 
5. Cardiac microRNA targets 
5.1 Identification of microRNA targets 
To comprehensively understand the miRNA function and potential therapeutic use in heart 
disease, identification and validation of miRNA targets is of fundamental importance. A 
large number of bioinformatic methods have been developed to predict miRNA targets 
based on the assumption that the 5’-nucleotides of miRNAs are most critical for target 
recognition (Lai, 2002; Lewis et al., 2003). Such methods easily result in the prediction of 
hundreds of potential miRNA targets which are difficult to validate using conventional 
means. Target accessibility is an important factor for miRNA target repression as nearly all 
the miRNA binding sites reside in the 3’-UTRs of target mRNA that is located in the 
unstable regions of mRNA structure calculated on the basis of free energy predictions and 
RNA structure (Zhao et al., 2005; Lee et al., 2002). Although various target prediction 
algorithms use the sequence complimentarity as a major determinant, newer tools are being 
developed as our understanding of the miRNA biology improves. In addition to the 
previous tools a novel miRNA target identification algorithms are being developed that also 
include target accessibility by evaluation of energy states of sequences flanking the miRNA 
target (Lewis et al., 2003; Lai, 2002). Such a tool has become a necessity as previous 
prediction algorithms seem to have higher levels of false positives. In this context, however 
it remains to be determined whether this stringent approach may identify less false-positive 
targets without missing others (Bruneau, 2005). A potential relationship between altered 
miRNA expression and changes in messenger RNA expression profiles in failing human left 
ventricles has recently been explored (Thum et al., 2007). Computational prediction 
identified multiple potential target genes with at least one binding site for highly 
upregulated miRNAs during heart failure. In contrast, transcriptome analysis conducted in 
parallel showed that theoretically predicted target genes were upregulated, demonstrating 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
232 
no obvious preponderance of gene repression (Thum et al., 2007). This obvious disconnect 
could be because the analysis was carried out at transcriptome level and not at a proteome 
level. It is potentially possible that the target proteins are significantly altered in response to 
miRNA alterations. The observed increase in miRNA transcripts could be due to feed back 
mechanism of reduced protein levels of the respective target proteins. These observations 
bring to focus our incomplete understanding of mRNA targeting by miRNA and we still 
have lot more to learn with regards to determining the underlying mechanisms regulating 
these processes. However, simultaneous use of current prediction algorithms and proteomic 
analysis should be able to provide a realistic idea on the target proteins. An important 
caveat that needs consideration is the sensitivity of proteome analysis which may still miss 
out on proteins altered at lower potency by miRNAs.  
5.2 MicroRNA targets in cardiac disease 
Despite the shortcomings of the tools available to accurately predict the targets, various 
studies have used traditional and non-traditional tools to verify and validate the targets of 
miRNAs. In many cases the targets have been identified in the knock-out or overexpression 
system which provides validity to the targets and it is further strengthened by the function of 
the target protein. We quote some of the examples below that provide a view point the way 
studies are currently being carried to unequivocally show that a specific protein is a miRNA 
target. Targeted deletion of miR-1-2 in mice causes 50% lethality mainly because of ventricular 
wall defects (Zhao et al., 2007) along with arrhythmias leading to sudden death. This has been 
linked to upregulation of Irx5, which is a target of miR-1 (Zhao et al., 2007). Conversely, it is 
also known that miRNA-1 expression resulted in repression of target KCNJ2 and GJA1 
channels that code for the main potassium channel subunit Kir2.1 and connexin (Yang et al., 
2007). This to a certain degree explains higher degree of arrhythmias found in patients with 
coronary artery disease where miRNA-1 expression is elevated and similar elevation is 
observed in mice following myocardial infarction. In contrast to these findings our studies in 
end-stage dilated cardiomyopathy and studies by others on aortic stenosis have found 
reduction in miRNA-1 expression (Naga Prasad et al., 2009). A preview of these studies show 
varied expression pattern of miRNA-1 based on the variations of diseases, biopsy locations, 
technical differences, or altered cellular composition of the biopsies. This indicates a need for 
appreciation of the differences so that in future a much more representative pattern develops 
for each of the altered miRNAs. In this context, miRNA-1 targets have been very well 
summarized that includes Ras GTPase-activating protein (RasGAP), cyclin-dependent kinase 9 
(Cdk9), Ras homolog enriched in brain (Rheb), and fibronectin (Latronico et al., 2007).  
On a similar note, miRNA-133 targets have also been well studied and they have been 
identified using in vitro and in vivo techniques (Care et al., 2007). They include Cdc42 
(implicated in cytoskeletal modifications during cardiac remodelling), Rho-A (a GTP–GDP-
binding molecule, also critical for hypertrophy), and NELF-A/WHSC2 (a nuclear factor 
involved in heart genesis). While Rho-A and Cdc42 have already been established as 
fundamental factors for cell growth, cytoskeletal reorganization, and regulation of contractility 
in cardiomyocytes, (Brown et al., 2006; Ke et al., 2004) the role of NELF-A/WHSC2 in cardiac 
hypertrophy is yet to be defined. Transduction of cardiomyocytes both in vitro and in vivo 
with an adenoviral vector containing a Whsc2 transgene resulted in protein synthesis 
inhibition, but induced the fetal gene program and upregulation of Rho-A, (Care et al., 2007) 
supporting the postulation that WHSC2 could play a selective role in hypertrophy. In addition 
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to targeting molecules modulating cardiac hypertrophy, miRNA-133 also targets molecules 
regulating cardiac conductance. In the diabetic heart, upregulation of miR-133 expression 
results in downregulation of protein expression of the ether-a-go-go-related gene (ERG), 
encoding the rapid delayed rectifier potassium channel (Xiao et al., 2007) .  
The studies on miRNA-133 targets are interesting suggesting a lot needs to be understood in 
terms of alteration of these miRNAs in stress results in a unique pathological phenotype. Such 
a view is further supported by studies on miRNA-208 which is expressed specifically in the 
cardiomyocytes (van Rooij et al., 2007). A major target of miRNA-208 is thrap1 [thyroid 
hormone receptor (THR)-associated protein 1] and reduction in the expression of miRNA-208 
results in loss of negative regulation on THRAP-1 (van Rooij et al., 2007). The resulting 
increase in THRAP 1 protein affects the THR-regulated expression of ǂ-MHC and ǃ-MHC, 
which are inversely regulated through a positive and negative thyroid hormone response 
element on their promoters. This shift in expression is thought to be the underlying factor for 
the blunted response to pressure overload in miR-208 knockout mice. In this context, our 
studies have shown that miRNA-7 is significantly down-regulated in end-stage human heart 
failure and upon TAC in mice and consistently its targets ERBB2 (epidermal growth factor 
receptor 2) and COL1A (Collagen 1) are upregulated (Naga Prasad et al., 2009). The above 
discussed studies are only a representative window on plethora of studies identifying targets 
for various miRNAs altered in conditions of cardiac stress. These studies have been discussed 
with an aim to provides a bird eye view of the complexity in regulation of target protein 
expression by miRNAs and to appreciate the diverse effects miRNA alteration can have in a 
pathology accounting for the phenotype.  
6. Specific molecules and network pathways altered in cardiac disease 
In this section we will specifically discuss the study initiated by our group to uncover the 
specific set of molecules and pathways altered during end stage human heart failure. Our 
published study comprehensively showed alterations in eight miRNAs which are significantly 
altered in heart failure out of which two new miRNAs that are yet to be implicated in cardiac 
pathophysiology. We have built signaling pathway networks using predicted targets for the 
miRNAs and identified nodal molecules that control these networks. Genome-wide profiling of 
miRNAs was performed using custom-designed miRNA microarray followed by validation on 
an independent set of samples. To gain an unbiased global perspective on regulation by altered 
miRNAs, predicted targets of eight miRNAs were analyzed using the Ingenuity Pathways 
Analysis network algorithm to build signaling networks and identify nodal molecules. The 
majority of nodal molecules identified in our analysis were targets of altered miRNAs and well 
known regulators of cardiovascular signaling. A heart failure gene expression data base was 
used to analyze changes in the expression patterns for these target nodal molecules (Naga 
Prasad et al., 2009). Indeed, expression of nodal molecules was altered in heart failure and 
inversely correlated to miRNA changes validating our analysis. Importantly, using network 
analysis we were successful in identification of a limited number of key functional targets that 
may regulate expression of the myriad proteins in heart failure and could be potential 
therapeutic targets. Furthermore, we have been able to independently see these 2 new miRNAs 
mir-7 and -378 in TAC mice hearts (Naga Prasad et al., 2009). We have shown miRNA-7 and -
378 to be downregulated in the end stage human heart failure and targets of miRNA-7, ERBB2 
and Col1A to be upregulated. miRNA-7-1 is encoded by the intron-1 of the HNRNPk gene. 
Similarly, we found miRNA-378 target SLC2A to be upregulated. Out of 1785 predicated 
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targets, 1716 could be mapped to signaling networks in the IPATM, and 995 predicated targets 
were found to be network-eligible. The 995 network-eligible candidates mapped to 43 networks 
that are predicted to be involved in the cross-talk with the peripheral molecules bridging 
different networks. A representative network with NFkB, a known mediator in cardiac 
dysfunction (Naga Prasad et al., 2009) as a central node, is shown in Fig. 2 wherein the members 
that network with NFkB are targets for the miRNAs 1, 29b, 125b, 181b 214, 342, and 378. As 
individual miRNA acts on each target, the net effect on the node would be the collective 
influence of all the members connected to the central node, NFkB (Fig. 2) Based on this 
consideration, we predicted that the complete NFkB regulatory signaling network (Fig. 2) 
would be significantly down-regulated in DCM since molecules in this network are predicted 
targets for up-regulated miRNAs 125b, 181b, 214, and 243.  
To directly evaluate whether nodal molecules are potential targets for altered miRNAs, 
immunoblotting studies in the end-stage human heart failure samples revealed an inverse 
co-relation with the level of respective miRNAs (Fig. 3). Immunoblotting showed ERBB2, 
HDAC4, COL1, MMP2, and TIMP2 were significantly up-regulated in human DCM (Fig. 3) 
and were inversely correlated to the down-regulation of their respective miRNAs. In 
contrast, STAT3 and E2F3 are down-regulated, consistent with the observation of up-
regulation of their respective miRNAs suggesting that expression of these molecules may be 
regulated by miRNAs. Interestingly, we did not observe changes in expression levels of RB1 
or EZH2 (Fig. 4) despite being predicted targets for miRNAs consistent with our data.  
 
 
Fig. 2. A representative network showing NF-κB as high connectivity node: The hub is the 
center of the web of signaling connections and NF-κB is connected to nearly all the molecules 
in the network. Altered miRNAs in end-stage heart failure are overlaid with their respective 
predicted targets. miRNA represented in green are downregulated and in red are upregulated 
in end-stage human dilated cardiomyopathy. Importantly, NF-κB is not a predicted target to 
any of the altered miRNAs in DCM, yet it could be regulated by alterations in miRNA targets. 
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7. miRNA databases and computational tools 
In recent years, many miRNA database systems have been developed and each of the 
databases has unique capabilities as they distinguish themselves by the types of data 
collected, the organization principles, and sources of the data contents. Therefore, it is 
important for researchers to use all of them to make an informed decision regarding 
execution of their experimental plan. These databases provide valuable resources to the 
research community towards understanding the functions of miRNAs in gene regulation. 
Critically, these databases contain miRNA sequences, annotations and nomenclature, 
miRNA targets and their relationships, as well as in some cases miRNA expression profiles 
in different cell types and tissues. 
 
 
Fig. 3. Immunoblotting in end stage human heart failure a, Western immunoblotting 
analysis was carried out on nonfailinghuman hearts (CON, controls; n=8), and hearts from 
patients diagnosed with DCM (n=8). 170 microgram of myocardial lysate was resolved with 
SDS-polyacrylamide gel and immunoblotted (IB) with respective antibodies. The blots were 
stripped and re-probed multiple times with various antibodies, including beta-actin 
antibody that was used to ensure equal loading. b, densitometric analysis in the DCM 
samples is represented as fold over nonfailing controls.*, p < 0.001 control versus DCM. 
miRBase (Griffiths-Jones et al., 2008) and Rfam (Gardner et al.,) are two major databases 
containing miRNA sequences and their annotations. miRBase database is an online 
repository for miRNA sequences and annotations that provides naming service for new 
miRNA genes isolated by researchers prior to publication. As of April 2011, miRBase 
contains 16772 mRNA entries from 153 species. Each entry represents a predicted hairpin 
portion of a miRNA transcript with information on the location and sequence of the mature 
miRNA as well as functional information/references. In this regard, Rfam database contains 
information about non-coding RNA families and annotations for family of RNA genes. As of 
June 2011, Rfam contains 1973 RNA families annotating over 2,756,313 regions in 1,723 
unique species. Each family in Rfam is represented by multiple sequence alignments, its 
consensus secondary structures, and the associated probabilistic covariance models. In 
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addition, Rfam coordinates a community annotation system providing access through 
Wikipedia allowing researchers to update entries and create families in the database.  
An essential aspect of the functional analysis of miRNAs is the annotation of their targets. 
Increasing number of miRNA target genes are being identified and confirmed 
experimentally and simultaneously numerous target prediction algorithms are being 
developed to enhance the certainty of prediction. miRNA target prediction data base 
TargetScan (Lewis et al., 2003) predicts miRNA targets in mammals by searching for the 
presence of conserved 8-mer and 7-mer sites that match the seed region of the miRNA. The 
criteria for prediction and ranking include stringent seed sequence base pairing, 
untranslated region (UTR) context, the degree of target sequence conservation across the 
range of species and finally the thermodynamic stability of the predicted pairings. In 
addition to TargetScan, there are also several other miRNA target prediction algorithms like 
PicTar (Lall et al., 2006), MiRanda (John et al., 2004) , EMBL (Stark et al., 2005). They all 
adopt similar criteria (of rigorous seed pairing, site number, site type and context, likelihood 
of preferential conservation, and predicted site accessibility) for the target prediction. 
Historically, during the early phases of target prediction algorithm development, the 
predicted targets would vary remarkably with many non-overlapping predictions. But with 
time, utilization of similar criteria has significantly reduced the discrepancies with many 
overlaps of predicted targets. Such cross-references across the data bases for the miRNA 
targets is provided by miRecords. This computational tool provides an integrated view of 
experimentally validated miRNA targets and displays predicted targets generated by 11 
established miRNA target prediction programs.  
Since targets for many miRNAs are being identified, there is an ongoing simultaneous effort 
to develop databases that exclusively provides information on validated miRNA targets like 
TarBase (Sethupathy et al., 2006) and miRTarBase. TarBase database collects manually 
curated and experimentally supported miRNA targets in animal species, plants and viruses. 
It includes more than 1300 targets and each target is described by the miRNA it binds, the 
experiments that tested this relationship and the link to citation. Database miRTarBase (Hsu 
et al.,) curates 3576 experimentally validated microRNA-target interactions between 657 
microRNAs and 2297 target genes among 17 species. In order to provide a disease 
perspective on the role of miRNA and their targets in pathology, a unique database 
miR2Disease [miR2Disease] has been generated. miR2Disease (Jiang et al., 2009) documents 
1939 curated miRNA-disease relationships between 299 human miRNAs and 94 human 
diseases. Each entry in the database contains information on the miRNA ID, the disease 
name, validated targets, expression patterns of the miRNA, a brief description of the 
miRNA-disease relationship and citation.  
Another important issue the readers need to appreciate is that despite the knowledge that 
there may be 1000 potential miRNA genes in the human genome, all of them have not yet 
been experimentally validated. These miRNA encoding gene predictions come from the 
sequence based curation of the genome to determine whether a specific DNA sequence 
characteristically fits the requirement for encoding a miRNA. RepTar (Elefant et al.,) is one 
such database that curates genome-wide predicted miRNAs of human and mouse. 
Furthermore, it can also predict cellular targets of human and mouse viral miRNAs. In 
addition to the miRNA sequence and target databases, a growing number of entries have 
been recorded at gene expression databases such as Gene Expression Omnibus (GEO) 
(Barrett et al.,) at NCBI and ArrayExpress (Brazma et al., 2006) Archive at EBI.  
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Although we are a long way away from validating all the predicted targets of altered 
miRNAs in heart failure, the predicted targets provide us a window to assess the global 
signaling pathways that could potentially be altered by the miRNAs in the heart failure. 
We have used this idea to build signaling networks of predicted targets of miRNAs 
altered in human heart failure which involves the role of miRNA target interaction with 
the biological pathways which ultimately generate the phenotype. A well known web-
based tool is the Ingenuity Pathway Analysis (IPA) which is commonly used to model, 
analyze, and understand biological data derived from mRNA/miRNA gene expression 
arrays, SNP microarrays, proteomics, as well as small scale experiments. The core of IPA 
is its knowledge database on genes, proteins, chemicals, and molecular relationships. The 
database contains highly structured information about molecular interactions and 
functional annotations as well as contextual details of the biological interactions. IPA 
provides modules that can be used to integrate data at multiple levels to obtain insight 
into the molecular interactions, cellular phenotypes and disease processes of the biological 
system like heart failure. The main analysis modules include 1) IPA Core Analysis for 
identifying signaling and metabolic pathways, molecular networks, and biological 
processes that are related to the biological data; 2) IPA-Metabolomics for extracting 
biological insight into cell physiology and metabolism; 3) IPA-Tox for analyzing toxicity 
of candidate compounds; and 4) IPA-Biomarker for identifying the most promising and 
relevant biomarker candidates within experimental datasets. In addition, IPA’s Path 
Designer provides researchers with help for transforming customized 
networks/pathways into pathway graphics for easy representation. It is well known 
historically that as the field evolves, so also the tools and miRNA target filter in the IPA 
analysis is one such evolution. miRNA Target Filter was introduced in the recent version 
of IPA (IPA 9.0) that allows researcher to examine both predicted and experimentally 
confirmed miRNA targets. Furthermore, it prioritizes targets based on related biological 
context and allows visualization of molecular interactions between miRNAs, their targets 
and other related molecules. IPA uses TargetScan database for predicted targets and 
TarBase for experimentally confirmed targets. 
8. miRNAs as therapeutic targets 
The current evidence from multiple studies show that miRNAs are altered with cardiac 
stress and genetic manipulation shows that miRNAs may actively contribute towards the 
deleterious cardiac phenotype. The regulation of cardiac phenotype by miRNAs, indicates 
that miRNAs can be used in therapeutic strategies to ameliorate deleterious outcomes. Since 
miRNAs are RNAs, they can be manipulated using the existing antisense and gene therapy 
approaches in vivo. Modified antisense oligonucleotides targeting the mature miRNA 
sequence, antimiRs, can reduce the levels of pathogenic or aberrantly expressed miRNAs 
(Krutzfeldt et al., 2005). Conversely, miRNA mimics can elevate the levels of miRNAs with 
beneficial outcomes (Xiao et al., 2007). Since miRNAs typically act as inhibitors of gene 
expression, the effect of adding specific miRNA mimics to a system is to decrease the 
expression of the mRNAs controlled by the miRNA. Conversely, the effect of inhibitors of 
specific miRNAs is to relieve the inhibition of the genes normally targeted by the miRNA. 
Thus, the primary effect of a miRNA inhibitor is activation of gene expression and a miRNA 
mimic is suppression of gene expression. 
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8.1 Antisense miRNA oligonucleotides and miRNA mimics 
Disease condition is contributed by upregulation or downregulation of miRNAs. In 
conditions of upregulation specific reduction of the miRNA would be therapeutically 
desirable. One of the efficient ways to inhibit miRNAs would be the use of chemically 
modified single-stranded reverse complement oligonucleotides. The synthetic reverse 
complement oligonucleotide approach affects miRNA levels by (1) binding the mature 
miRNA within the RISC and acting as a competitive inhibitor; (2) binding to the pre-miRNA 
and preventing its processing or entry into the RISC; (3) interfering with the processing or 
export of the pre- or pri-miRNA from the nucleus. In any case, the net result is a reduction 
in the concentration of a specific miRNA-programmed RISC. This approach is similar in 
concept to traditional antisense targeting of mRNAs, except the number of targeting sites for 
a miRNA is very limited. Although conceptually comparable, only a handful of 
modifications have been achieved for inhibition of miRNAs. Such a technique has been 
effectively used to knock down let-7 in Drosophila (Hutvagner, Simard et al. 2004) while 
miRNA-122 was the first mammalian miRNA to be targeted for liver (Krutzfeldt et al., 2005). 
In this context, miRNA-133 (Altuvia et al., 2005) and miRNA-29 (van Rooij et al., 2008) have 
been effectively used to alter cardiac phenotype suggesting that this specific technique 
would be a viable option for therapeutic strategy. More recently, the technique of modifying 
the oligonucleotides with 2’O-methoxyethyl phosphorothioate is being extensively used as it 
seems to provide long term stability for the administered oligos thus extending the 
beneficial effects in vivo.  
Anti-sense oligos can be used in conditions of targeting upregulated miRNAs and in 
conditions where reduction in miRNA level causes a disease state, beneficial therapeutic 
approach would be to increase its concentration. Instead of delivering the single-stranded 
oligonucleotide equivalent of the mature miRNA, an increase in the effective concentration 
of a reduced miRNA can be achieved through the use of synthetic RNA duplexes in which 1 
strand is identical to the native miRNA. In this case, short double stranded oligonucleotides 
are designed in which 1 strand is the mature miRNA sequence (guide strand) and a 
complimentary or partially complementary stand is complexed with the mature miRNA 
sequence (passenger strand). The double stranded structure is required for recognition and 
loading into the RISC (Martinez et al., 2002). The only caveat in this kind of the design is to 
make sure that the passenger strand is eliminated and does not act as a new miRNA that 
may complicate the interpretation. Alternatively, approaches similar to that undertaken 
with siRNA using bioinformatic and chemical modification can be used and provides 
attractive means to elevate miRNA levels.  
8.2 Therapeutic targeting of miRNA and challenges 
Despite the ability to manipulate miRNAs in vivo to provide unique opportunities 
therapeutically, miRNA-based therapeutics pose challenges that are different from those 
associated with classic drugs. One of the major stumbling blocks for miRNA targeting is the 
issue of specificity. While specificity for a single cellular target is vital in classic drugs, 
miRNAs have numerous molecular targets raising the possibility that targeting of a miRNA 
may perturb multiple cellular functions both deleterious as well as beneficial. Since miRNAs 
are new set of molecules that are being targeted, better understanding of pharmacokinetics, 
biodistribution, and cell penetration is required to develop these as therapeutics. It is known 
that native nucleic acids are rapidly degraded by a variety of nucleases and 
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phosphodiesterases in blood. Furthermore, biological environments and requirement of 
chemical modifications on the synthetic nucleotide derivatives may alter miRNA 
biophysical properties reducing the efficiency of therapeutic function. In this regards, 
several modifications that increase the stability of the oligonucleotides, including 
phosphorothioate, 2’-O-methyl, and 2’-fluoro substitutions can be effectively put to use in 
developing therapeutic strategies (Soutschek et al., 2004).  
8.3 Methods of Delivery 
In addition to efforts on developing miRNAs that are stable by modification, intense efforts 
are also ongoing to identify agents capable of targeted delivery of nucleic acids to tissues 
and cells. Delivery approaches can be broadly divided into 2 categories, conjugation and 
formulation. Conjugation strategies include direct attachment of targeting and cell-
penetrating peptides, antibodies, and other bioactive molecules to the oligonucleotide. 
Formulation approaches vary broadly and include complex lipid emulsions from natural 
sources, synthetic liposomes, polyplexes, polymers and nanoparticles. To enter mammalian 
cells, the reverse-complement oligonucleotide needs to cross the lipid bilayer of the cell 
membrane and can be achieved by packaging the oligonucleotide into liposomes or 
nanoparticles that facilitates endocytosis. Alternatively, the oligonucleotide can be linked to 
a lipophilic moiety or receptor ligand, such as cholesterol that seems to greatly enhance 
cellular uptake (Soutschek et al., 2004). Despite significant advances in systemic delivery 
technology, most nucleic acid delivery agents developed to date have demonstrated efficacy 
in delivery to the liver. Therefore, effective delivery approaches especially to the heart 
would be a great stepping stone in the direction towards use of synthetic nucleic acids as 
therapeutics for cardiovascular disease. Interestingly, heart failure affords a unique 
opportunity to expand the potential for local delivery through the use of catheters providing 
additional level of sophistication.  
9. Conclusions 
It is remarkable to consider that miRNAs were first shown to function in mammals less than 
a decade ago, and the concept of miRNA manipulation in vivo to regulate disease-related 
processes is already becoming a feasible future therapeutic approach. Moreover, the rapidly 
expanding number of miRNAs makes it likely that the relatively few miRNAs studied to 
date represent only a subset of the miRNAs of interest in human disease. Given the 
established involvement of miRNAs in many facets of heart disease, it becomes pertinent to 
understand the underlying basis for its contributing role before taking on miRNA based 
human trials. Understanding the role of miRNAs in regulating various targets is the weakest 
link in this chain of fast moving area of miRNA that needs effort and resources. We believe 
the efforts are needed simultaneously in the direction of indepth contemporary proteomics 
along with assessment of miRNAs providing platform for linking miRNA to target protein 
expression which are the ultimate determinants of the phenotype. Therefore, identifying 
and validating miRNA targets are of paramount importance and establishment of the 
miRNA targets will provide a sound foundation for development of global signaling 
networks. Understanding the global regulation of networks by a miRNA rather than a 
specific target would be a more feasible approach to understand the overall function of 
miRNAs in development and disease conditions as a single miRNA could target both 
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synergistic as well as antagonistic pathways. Appreciation of this unique regulation by 
miRNAs in physiology as well as pathology is the incentive to develop tools and technology 
to better understand the role of miRNAs in effecting global change rather than specific 
molecules in a given pathway.  
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